Skip to main content
SpringerLink
Log in

Erectile Dysfunction

  • Chapter
  • First Online:
Comprehensive Cardiovascular Medicine in the Primary Care Setting

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 989 Accesses

Abstract

Erectile dysfunction is commonly defined as the inability to attain or maintain a penile erection sufficient for satisfactory sexual intercourse. The prevalence, as estimated in a cross-sectional national probability survey in the United States (men aged 40 years and more, May 2001–January 2002), was 22% with significant increase with aging (Laumann, J Sex Med, 4:57–65, 2007). A similar prevalence of 19.2% was found in an urban area in Germany (30–80 years of age), with an increase from 2% among the youngest group to 53% in the oldest group (Braun, Int J Impot Res, 12:305–311, 2000). Twenty-six new cases per 1000 men were the estimated annual incidence of erectile dysfunction determined in the Massachusetts Male Aging Study (40- to 69-year-old men) (Johannes, J Urol, 163:460–463, 2000).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang JH. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 2007;4:57–65.

    Article  Google Scholar 

  2. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res. 2000;12:305–11.

    Article  CAS  Google Scholar 

  3. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–3.

    Article  CAS  Google Scholar 

  4. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med. 2000;109:3S–12S.

    Article  Google Scholar 

  5. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699–709.

    CAS  PubMed  Google Scholar 

  6. Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. 1996;54:1675–82.

    CAS  PubMed  Google Scholar 

  7. Nicolosi A, Moreira E, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–6.

    Article  Google Scholar 

  8. NIH Consensus Development Panel on Impotence. Impotence. JAMA. 1993;270:83–90.

    Article  Google Scholar 

  9. Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc. 2002;102:S1–6.

    PubMed  Google Scholar 

  10. McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–32.

    Article  CAS  Google Scholar 

  11. Brock GB, Lue TF. Drug-induced male sexual dysfunction. An update. Drug Saf. 1993;8:414–46.

    Article  CAS  Google Scholar 

  12. Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev. 1999;18:5–24.

    CAS  PubMed  Google Scholar 

  13. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64.

    Article  CAS  Google Scholar 

  14. Roth A, Kalter-Leibovici O, Kerbis Y, et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol. 2003;26:25–30.

    Article  Google Scholar 

  15. Moulik PK, Hardy KJ. Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med. 2003;20:290–3.

    Article  CAS  Google Scholar 

  16. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet. 1985;1:181–4.

    Article  CAS  Google Scholar 

  17. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;6:19–24.

    Google Scholar 

  18. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179–84.

    Article  Google Scholar 

  19. O’Kane PD, Jackson G. Erectile dysfunction: is there silent obstructive coronary artery disease? Int J Clin Pract. 2001;55:219–20.

    PubMed  Google Scholar 

  20. Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22–6.

    Article  Google Scholar 

  21. Billups KL. Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. Curr Sex Health Rep. 2004;1:137–41.

    Article  Google Scholar 

  22. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44:360–5.

    Article  Google Scholar 

  23. Hodges LD, Kirby M, Solanki J, et al. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61:2019–5.

    Article  CAS  Google Scholar 

  24. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006;27:2632–9.

    Article  Google Scholar 

  25. Peyton CC, Colaco MA, Kovel RC, et al. Erectile dysfunction is predictive of endothelial dysfunction in a well visit population. J Urol. 2016;195:1045–50.

    Article  Google Scholar 

  26. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res. 2004;16:350–3.

    Article  CAS  Google Scholar 

  27. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170:S46–50.

    Article  Google Scholar 

  28. Dorey G. Is smoking a cause of erectile dysfunction? A literature review. Br J Nurs. 2001;10:455–65.

    Article  CAS  Google Scholar 

  29. Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health. 1998;118:151–5.

    Article  CAS  Google Scholar 

  30. Mirone V, Imhimbo C, Bortolotti A, et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur Urol. 2002;41:294–7.

    Article  Google Scholar 

  31. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–6.

    Article  CAS  Google Scholar 

  32. Romeo JH, Seftel AD, Madhum ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163:788–91.

    Article  CAS  Google Scholar 

  33. Wassmann S, Laufs U, Bäumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001;37:1450–7.

    Article  CAS  Google Scholar 

  34. Herrmann HC, Levine LA, Macaluso J, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med. 2006;3:303–8.

    Article  CAS  Google Scholar 

  35. Carvajal A, Macias D, Sáinz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf. 2006;29:143–9.

    Article  CAS  Google Scholar 

  36. Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. J Clin Pract. 2006;60:141–5.

    Article  CAS  Google Scholar 

  37. Ralph D, McNicholas T. Erectile dysfunction alliance. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499–503.

    Article  CAS  Google Scholar 

  38. Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A system review. Fam Pract. 2002;19:95–8.

    Article  Google Scholar 

  39. Schachter M. Erectile dysfunction and lipid disorders. Curr Med Res Opin. 2000;16:S9–S12.

    Article  Google Scholar 

  40. Carvajal A, Lérida MT, Sánchez A, Martín LH, de Diego IM. ACE inhibitors and impotence: a case series from the Spanish drug monitoring system. Drug Saf. 1995;13:130–1.

    Article  CAS  Google Scholar 

  41. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321:336–41.

    Article  CAS  Google Scholar 

  42. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2:447–55.

    Article  CAS  Google Scholar 

  43. Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med. 2016;13:887–904.

    Article  Google Scholar 

  44. Gianetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12:185.

    Article  Google Scholar 

  45. Bohlen JG, Held JP, Sanderson MO, Patterson RP. Heart rate, rate–pressure product and oxygen uptake during four sexual activities. Arch Intern Med. 1984;144:1745–8.

    Article  CAS  Google Scholar 

  46. Larson JL, McNaughton MW, Kennedy JW, Mansfield LW. Heart rate and blood pressure response to sexual activity and a stair-climbing test. Heart Lung. 1980;9:1025–30.

    CAS  PubMed  Google Scholar 

  47. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:175–81.

    Article  CAS  Google Scholar 

  48. Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96:313–21.

    Article  Google Scholar 

  49. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87:766–78.

    Article  Google Scholar 

  50. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125:1058–72.

    Article  Google Scholar 

  51. Hatzimouratidis K, Salonia A, Adaikan G, et al. Pharmacotherapy for erectile dysfunction: recommendations from the fourth International Consultation for Sexual Medicine (ICSM 2015). J Sex Med. 2016;13:465–88.

    Article  Google Scholar 

  52. Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract. 2010;64:240–55.

    Article  CAS  Google Scholar 

  53. Mittleman MA, Glasser DB, Orazem J. Clinical trials of sildenafil citrate demonstrate no increase in risk of myocardial infarction and cardiovascular death compared to placebo. Int J Clin Pract. 2003;57:597–600.

    CAS  PubMed  Google Scholar 

  54. Hazell L, Boshier A, Harris S, et al. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischemic heart disease. BJU Int. 2007;99:387–93.

    Article  CAS  Google Scholar 

  55. Kloner RA, Henderson L. Sexual function in patients with chronic angina pectoris. Am J Cardiol. 2013;11:1671–6.

    Article  Google Scholar 

  56. Swearingen D, Nehra A, Morelos S, et al. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;2013:212248.

    PubMed  PubMed Central  Google Scholar 

  57. Reffelmann T, Kloner RA. Cardiovascular effects of phosphodiesterase 5 inhibitors. Curr Pharm Des. 2006;12:3485–94.

    Article  CAS  Google Scholar 

  58. Reffelmann T, Kloner RA. Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2007;8:965–74.

    Article  CAS  Google Scholar 

  59. Reffelmann T, Kloner RA. The cardiovascular safety of tadalafil. Expert Opin Drug Saf. 2008;7:43–52.

    Article  CAS  Google Scholar 

  60. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C–44C.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik II, Klinikum Idar-Oberstein, Idar-Oberstein, Germany

    Thorsten Reffelmann

  2. Huntington Medical Research Institutes, Pasadena, CA, USA

    Robert A. Kloner

Authors
  1. Thorsten Reffelmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Kloner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert A. Kloner .

Editor information

Editors and Affiliations

  1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Peter P. Toth

  2. Cardiovascular Division, Harvard Medical School Brigham & Women’s Hospital, Boston, MA, USA

    Christopher P. Cannon

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Reffelmann, T., Kloner, R.A. (2019). Erectile Dysfunction. In: Toth, P., Cannon, C. (eds) Comprehensive Cardiovascular Medicine in the Primary Care Setting. Contemporary Cardiology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-97622-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-97622-8_20

  • Published:

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-97621-1

  • Online ISBN: 978-3-319-97622-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation